SACRAMENTO, Calif., Oct. 2, 2024 /PRNewswire/ -- Ambetter from Health Net, a product offered by a Centene Corporation (NYSE: CNC) company which provides insurance to under-insured and uninsured populations through Covered California, the State Based Exchange, will offer Californians a variety of affordable health insurance plans in plan year 2025. Open enrollment for Covered California runs from Nov. 1, 2024, through Jan. 31, 2025. Enroll by Dec. 31, 2024, for coverage starting Jan. 1, 2025, and Jan. 31, 2025, for coverage starting Feb. 1, 2025.
"Health Net is committed to making quality, affordable health insurance accessible to all Californians," said Plan President and Chief Executive Officer of Health Net Brian Ternan. "By offering a diverse range of Ambetter from Health Net HMO and PPO options, we continue our dedication to providing comprehensive coverage that supports healthier lives for everyone."
Ambetter from Health Net offers its members access to quality care, convenient services and valuable rewards. 2025 benefits and offerings include:
Below is the full list of counties in which Ambetter from Health Net will be offered:
*Partial region coverage in Placer, Kern, Riverside and San Bernardino Counties.
California residents interested in learning more about Ambetter from Health Net or enrolling in a health plan during the open enrollment period may visit https://ifp.healthnetcalifornia.com/.
About Health Net, Inc.
Ambetter Health health maintenance organization (HMO) and preferred provider organization (PPO) plans are offered by Health Net of California, Inc. (Health Net). Health Net of California, Inc. is a subsidiary of Health Net, LLC. and Centene Corporation. Health Net is a registered service mark of Health Net, LLC. All rights reserved. This is a solicitation for insurance. For information on your right to receive Ambetter from Health Net plans free of discrimination, or your right to receive language, auditory and/or visual assistance services, please visit https://www.healthnet.com/content/healthnet/en_us/disclaimers/legal/non-discrimination-notice.html and scroll to the bottom of the page.
Last Trade: | US$63.52 |
Daily Change: | 1.74 2.82 |
Daily Volume: | 5,286,820 |
Market Cap: | US$33.410B |
October 30, 2024 October 25, 2024 September 11, 2024 August 29, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB